Research Progress of Chinese Medicine Monomers in Treatment of Cholangiocarcinoma

WANG Xiang; WANG Xiao-qing; LUO Kai; BAI He; QU Jia-lin; ZHANG Gui-xin

doi:10.1007/s11655-024-4203-9

Your Location：

Home >

Browse articles >

Research Progress of Chinese Medicine Monomers in Treatment of Cholangiocarcinoma

Review | Updated：2025-01-21

- Research Progress of Chinese Medicine Monomers in Treatment of Cholangiocarcinoma
- Chinese Journal of Integrative Medicine Vol. 31, Issue 2, Pages: 170-182(2025)
- Affiliations：
  
  1.Department of General Surgery, the Second Hospital of Dalian Medical University, Dalian, Liaoning Province (116027), China
  2.Clinical Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province (116021), China
  3.Hepatobiliary Surgery Department, Shandong Provincial Third Hospittal, Shandong University, Jinan (250031), China
  4.Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, Liaoning Province (116044), China
- Author bio：
  
  Prof. ZHANG Gui-xin, E-mail: zhangguixin2024@163.com
- Funds：
- DOI：10.1007/s11655-024-4203-9
  CLC：
- Published：2025-02，
  
  Published Online：29 October 2024，
  
  Accepted：2024-07-16
- Accepted：
Scan QR Code
WANG XIANG, WANG XIAO-QING, LUO KAI, et al. Research Progress of Chinese Medicine Monomers in Treatment of Cholangiocarcinoma. [J]. Chinese journal of integrative medicine, 2025, 31(2): 170-182.
DOI：

WANG XIANG, WANG XIAO-QING, LUO KAI, et al. Research Progress of Chinese Medicine Monomers in Treatment of Cholangiocarcinoma. [J]. Chinese journal of integrative medicine, 2025, 31(2): 170-182. DOI： 10.1007/s11655-024-4203-9.

摘要

Abstract

Cholangiocarcinoma (CCA) is a malignant tumor originating from cholangiocytes. However

it remains unclear about the pathogenesis of this carcinoma

which may be related to multiple factors. Currently

CCA is mainly treated by surgery

chemotherapy

and radiotherapy. Among them

surgery is the only potentially curative option for CCA. Nevertheless

the high malignancy and asymptomatic nature of CCA may lead to poor treatment outcomes. It has been demonstrated that Chinese medicine (CM) plays a significant role in various antitumor applications. Meanwhile

CM exhibits fewer side effects and high availability. Moreover

the

in vitro

application of CM monomers has been explored in many domestic and foreign studies. This article mainly reviews

the signaling pathways and molecular mechanisms of CM monomers in the treatment of CCA in recent years. These findings are expected to provide new insights into the treatment of CCA.

关键词

Keywords

cholangiocarcinomaChinese medicinemonomersantitumorsignaling pathwaysmolecular mechanismsreview

references

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Pharmacological Mechanism of Chinese Medicine in Systemic Lupus Erythematosus: A Narrative Review

Targeting Therapeutic Windows for Rheumatoid Arthritis Prevention

Progress on Regulation of NLRP3 Inflammasome by Chinese Medicine in Treatment of Ulcerative Colitis

Mechanism Study on Chinese Medicine in Treatment of Nodular Goiter

Research on Mechanisms of Chinese Medicines in Prevention and Treatment of Postoperative Adhesion

Related Author

ZHU Bo-yu

LIU Zhi-chao

ZHAO Zhen-xi

HUANG Hui-ping

ZHANG Na

XIA Jia

CHEN Wei-wei

GAO Kai-xin

Related Institution

Department of Rheumatology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine

Section of Rheumatology and Immunology Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

The Second Clinical Medical College, Guangzhou University of Chinese Medicine

State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangzhou University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰